FREE Equity Delivery and MF
Flat ₹20/trade Intra-day/F&O
|
Comparision between Concord Biotech IPO and Senco Gold IPO.
Concord Biotech IPO is a Mainline Book Built Issue IPO proposed to list at BSE, NSE while Senco Gold IPO is a Mainline Book Built Issue proposed to list at BSE, NSE.
Concord Biotech IPO | Senco Gold IPO | |
---|---|---|
Logo | ||
Issue Category | Mainline | Mainline |
Issue Type | IPO | IPO |
Process Type | Book Built Issue | Book Built Issue |
Listing At | BSE, NSE | BSE, NSE |
Lead Managers | Kotak Mahindra Capital Company Limited Citigroup Global Markets India Private Limited Jefferies India Private Limited |
Iifl Securities Ltd Ambit Private Limited SBI Capital Markets Limited |
Registrar | Link Intime India Private Ltd | Kfin Technologies Limited |
Market Maker | ||
DRHP | DRHP | DRHP |
RHP | RHP | RHP |
Anchor Investor | Anchor Investor | Anchor Investor |
IPO Allotment URL | IPO Allotment URL | IPO Allotment URL |
The total issue size of Concord Biotech IPO is up to ₹1,551.00 Cr whereas the issue size of the Senco Gold IPO is up to ₹405.00 Cr. The final issue price of Concord Biotech IPO is ₹741.00 per share and of Senco Gold IPO is ₹317.00 per share.
Concord Biotech IPO | Senco Gold IPO | |
---|---|---|
Face Value | ₹1 per share | ₹10 per share |
Issue Price (Lower) | ₹705.00 per share | ₹301.00 per share |
Issue Price (Upper) | ₹741.00 per share | ₹317.00 per share |
Issue Price (Final) | ₹741.00 per share | ₹317.00 per share |
Discount (Retail) | ||
Discount (Employee) | ₹70.00 per share | |
Market Lot Size | 20 shares | 47 shares |
Fresh Issue Size | 85,17,350 shares | |
Fresh Issue Size (Amount) | up to ₹270.00 Cr | |
OFS Issue Size | 2,09,25,652 shares | 42,58,675 shares |
OFS Issue Size (Amount) | up to ₹1,551.00 Cr | up to ₹135.00 Cr |
Issue Size Total | 2,09,25,652 shares | 1,27,76,025 shares |
Issue Size Total (Amount) | up to ₹1,551.00 Cr | up to ₹405.00 Cr |
Concord Biotech IPO opens on Aug 04, 2023, while Senco Gold IPO opens on Jul 04, 2023. The closing date of Concord Biotech IPO and Senco Gold IPO is Aug 08, 2023, and Jul 06, 2023, respectively.
Concord Biotech IPO | Senco Gold IPO | |
---|---|---|
Anchor Bid Date | Aug 03, 2023 | Jul 03, 2023 |
Issue Open | Aug 04, 2023 | Jul 04, 2023 |
Issue Close | Aug 08, 2023 | Jul 06, 2023 |
Basis Of Allotment (Tentative) | Aug 11, 2023 | Jul 11, 2023 |
Initiation of Refunds (Tentative) | Aug 14, 2023 | Jul 12, 2023 |
Credit of Share (Tentative) | Aug 17, 2023 | Jul 13, 2023 |
Listing date (Tentative) | Aug 18, 2023 | Jul 14, 2023 |
Anchor Lockin End date 1 | Sep 10, 2023 | Aug 10, 2023 |
Anchor Lockin End date 2 | Nov 09, 2023 | Oct 09, 2023 |
Concord Biotech IPO P/E ratio is 32.29, as compared to Senco Gold IPO P/E ratio of 15.53.
Concord Biotech IPO | Senco Gold IPO | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Financial |
Amount in ₹ Crore |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Promoter Shareholding (Pre-Issue) | 44.08% | 76.92% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Promoter Shareholding (Post-Issue) | 44.08% | 68.48% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
P/E Ratio | 32.29 | 15.53 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Market Cap | ₹7752.06 Cr. | ₹2462.00 Cr. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ROE | 20.06%% | 18.9%% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ROCE | 24.27%% | 14.2%% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt/Equity | 1.25 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
EPS | ₹20.79 | ₹22.93 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
RoNW | 20%% | 18.96%% |
In the Concord Biotech IPO retail investors (RII) are offered 73,20,479 shares while in Senco Gold IPO retail investors are offered 73,20,479 shares. Qualified institutional buyers (QIB) are offered 41,83,130 shares in Concord Biotech IPO and 25,55,203 shares in Senco Gold IPO.
Concord Biotech IPO | Senco Gold IPO | |
---|---|---|
Anchor Investor Reserveration | 62,74,695 shares | 38,32,807 shares |
Market Maker Reserveration | ||
QIB | 41,83,130 shares | 25,55,203 shares |
NII | 31,37,348 shares | 19,16,404 shares |
RII | 73,20,479 shares | 44,71,609 shares |
Employee | 10,000 shares | 0 shares |
Others | ||
Total | 1,46,50,957 shares | 89,43,216 shares |
Concord Biotech IPO subscribed 24.87x in total, whereas Senco Gold IPO subscribed 77.25x.
Concord Biotech IPO | Senco Gold IPO | |
---|---|---|
QIB (times) | 67.67x | 190.56x |
NII (times) | 16.99x | 68.44x |
Big NII (times) | 19.30x | 72.05x |
Small NII (times) | 12.37x | 61.23x |
RII (times) | 3.78x | 16.28x |
Employee (times) | 24.48x | |
Other (times) | ||
Total (times) | 24.87x | 77.25x |
Add a public comment...
Rs 0 Account Opening Fee
Free Eq Delivery & MF
Flat ₹20 Per Trade in F&O
FREE Intraday Trading (Eq, F&O)
Flat ₹20 Per Trade in F&O
|